Kornimate/medical-research-clean huggingface dataset:
mindfulness-based cognitive therapy in a clinical sample of ocd patients

Conditions: Obsessive-Compulsive Disorder

Summary: obsessive compulsive disorder (ocd) is a chronic and debilitating disorder known to have reported lifetime prevalence in the range of 2%. ocd is most commonly treated with cognitive behavioural therapy (cbt) and/or pharmacotherapy. however, some studies suggest challenges with cbt in retaining gains long term, and while 60-80% of ocd patients respond to sri treatment, partial symptom reduction is substantial. investigations into the effectiveness of alternative, cost-effective treatment modalities are thus needed. mindfulness, defined as paying attention in a particular way (on purpose, in the present moment and nonjudgmentally), promotes awareness and attention to internal experience and has been shown to reduce symptoms of anxiety and depression. a number of controlled studies have found mindfulness-based cognitive therapy (mbct) to be effective for depression, social anxiety disorder, and generalized anxiety disorder, but few have tested its effect on obsessive compulsive disorder (ocd). moreover, those studies examining mbct in ocd focused on clinical case studies and non-clinical samples. this study proposes to examine the effect of mbct in clinical practice, in a randomized sample of patients with ocd whom are on a clinic wait list. as patients are allocated to the wait list, they will be randomly assigned to receive either 10 weeks of group mbct or wait list as per usual. it is hypothesized that subjects randomly assigned to the mbct treatment group, compared to those in the wait list control group, will see greater reductions in self-reported measures of ocd symptom severity and improvement in other measures of mindfulness, mood and level of functioning. the results of this pilot study, if successful, will provide evidence towards another route by which patients can improve their ocd while waiting for clinic services or consultation. results will also lend more evidence as to whether mbct is effective as a stand-alone treatment for clinical ocd, which will inform further investigations into the potential addition of mindfulness techniques to standard care.


Eligibility criteria:
inclusion criteria: * referred for treatment services at the frederick w. thompson anxiety disorder centre at sunnybrook health sciences centre * primary diagnosis of ocd * ability to communicate in written and spoken english exclusion criteria: * those with active substance abuse/dependence within 3 months * suspected organic pathology * recent suicide attempt/active suicidality * current self-injurious behaviour * active bipolar or psychotic disorder * previous completion of an mbct course (≥ 8 weeks) * previous completion of an ocd-specific course of cbt (≥ 8 weeks) * previous completion of a general course of cbt (≥ 8 weeks) in the past 3 years

Keywords: mindfulness-based cognitive therapy mindfulness
a study to assess change in functioning and health related quality of life in adult participants with chronic lymphocytic leukemia (cll) receiving oral treatments in routine clinical practice in spain

Conditions: Chronic Lymphocytic Leukemia

Summary: chronic lymphocytic leukemia (cll) is the most common leukemia in the western world. since in most cases cll remains an incurable disease, the goals of therapy are to improve quality of life and to prolong survival. this study will evaluate the participant's related outcomes and experience of cll in adult participants who are treated in the spain. study participants will receive oral treatments for cll as prescribed by their study doctor in accordance with approved local label. adult participants prescribed various treatments will be enrolled. around 132 participants will be enrolled in the study in sites in spain. participants will receive oral treatments for cll according to the approved local label. the overall study duration will be 18 months. there is expected to be no additional burden for participants in this trial. all study visits will occur during routine clinical practice.


Eligibility criteria:
inclusion criteria: * have documented chronic lymphocytic leukemia (cll) according to international workshop on chronic lymphocytic leukemia (iwcll) criteria. * under oral treatment for cll, either first-line or relapsed/refractory (r/r) therapy. * treatment for cll started 9 months (+/- 4 weeks) before inclusion for first-line therapy or 21 months (+/- 4 weeks) before inclusion for r/r, under authorized conditions. * in the opinion of the investigator, cognitive ability to understand and answer the questionnaires specified in the study protocol. * able to comply with the study protocol in the investigator's judgment. exclusion criteria: * currently receiving any chemotherapy or chemoimmunotherapy. * transformation of cll to aggressive non-hodgkin's lymphoma (nhl) (richter's transformation or pro-lymphocytic leukaemia). * currently participating in interventional research (not including non-interventional study, post-marketing observational study, or registry participation). * any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study.

Keywords: chronic lymphocytic leukemia bruton tyrosine kinase inhibitor patient-reported outcomes measure patient-reported experience measure venetoclax venclexta venclyxto abt-199 patient preferences cancer providence
effective treatment for prescription opioid abuse

Conditions: Prescription Opioid Dependence

Summary: there has been an alarming increase in abuse of prescription opioids in recent years. this project aims to develop an effective outpatient treatment for prescription opioid (po) abuse that combines an intensive behavioral therapy with a pharmacotherapy regimen of buprenorphine detoxification and naltrexone maintenance.

there has been an alarming increase in abuse of prescription opioids in recent years. this project aims to develop an effective outpatient treatment for prescription opioid (po) abuse that combines an intensive behavioral therapy with a pharmacotherapy regimen of buprenorphine detoxification and naltrexone maintenance. aim 1) conduct a randomized, three-parallel-groups clinical trial (study 1) to determine a buprenorphine dose-tapering schedule that prevents the poor retention and relapse that undermine many opioid detoxification regimens. aim 2) conduct a randomized, three-parallel-groups clinical trial (study 2) to determine a duration of naltrexone therapy that sustains opioid abstinence following the buprenorphine detoxification.

Eligibility criteria:
inclusion criteria: * for inclusion in the proposed studies, subjects must be \> 18 years old and in good health. subjects must meet dsm-iv criteria for opioid dependence and fda qualification criteria for buprenorphine treatment, including a history of opioid dependence and significant current opioid use (i.e., opioid-positive urines). subjects must also be seeking or willing to accept opioid detoxification. exclusion criteria: * because the primary focus of the proposed research is to develop an efficacious intervention for prescription opioid abuse that employs a buprenorphine taper and subsequent naltrexone maintenance, individuals who require ongoing opioid therapy for pain or other chronic medical conditions will be excluded from participating. * individuals with evidence of an active psychiatric disorder that may interfere with consent or participation in the research (e.g., psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., cardiovascular disease) or who are pregnant or nursing will be excluded from participation.

Keywords: prescription opioid opioid detoxification buprenorphine naltrexone community reinforcement approach prescription opioid abuse
clinical study of hypoxia-stressed bone marrow mononuclear cell transplantation to treat heart diseases

Conditions: Myocardial Infarction (MI) or Acute Myocardial Infarction (AMI)

Summary: the purpose of this study, is to determine the differences of clinical outcomes between hypoxic pre-treatment group and control group in bone marrow stem cell transplantation (bm-sct) to treat acute myocardial infarction (ami); and to evaluate the safety of both treatments. heart failure patients underwent pci treatment after ami and with informed consent, are randomized allocation into hypoxic pre-treated bm-sct group, normoxic pre-treated bm-sct group, and control group. cell resuspension is intracoronary injected into patients receiving coronary angiography, il-6, crp, tnf and bnp are detected; echocardiography, cardiac mri and ect are analyzed to evaluate heart function and alive myocardial cells. holter's ecg monitor is employed to observe arrhythmia and embolism. we hypothesize that, by receiving hypoxic pre-treated bm-sct, impaired heart function will be reversed in heart failure patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of acute myocardial infarction(within one month); * age under 65; * infarction related wall motion abnormality on echocardiography; * infarction related timi flow grades 3 on coronary angiography during cell injection; * informed consent; exclusion criteria: * active infection, or hematopoietic malignancy; * patients have tumor or other lethal diseases; * informed refusal
a study to evaluate the efficacy of tolterodine on specific symptoms in adult patients with overactive bladder.

Conditions: Urinary Bladder, Overactive

Summary: the purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with oab.


Eligibility criteria:
inclusion criteria: * self-reported symptoms of oab for ≥ 3 months prior to screening * oab as defined by urinary frequency (a minimum of 8 micturitions per 24 hours) * urgency (defined as a strong and sudden desire to urinate) or urge incontinence a minimum of 2 episodes in 3 days, as confirmed by the micturition diary between screening and baseline * patients who describe the degree of bothersomeness of their most bothersome oab symptom as "moderately ", "a great deal ", or "a very great deal" per the oab bother rating scale exclusion criteria: * any condition that would contraindicate their usage of tolterodine once daily, including: narrow angle glaucoma, urinary retention, gastric retention * any clinically significant local urinary tract pathology which could mimic the symptoms of oab, such as infection or hematuria * stress incontinence, functional, or overflow incontinence as determined by the investigator * symptomatic acute urinary tract infection (uti) during the run-in period, or recurrent utis defined by treatment for symptomatic uti \>3 times in the 12 months prior to participation in this clinical trial * clinically significant urinary tract obstruction * history of lower urinary tract surgery (e.g. prostate removal or destruction, incontinence surgery) within the past 3 months * clinically significant interstitial cystitis or significant bladder pain syndrome
walking capacity in parkinson's disease (pd-walk)

Conditions: Idiopathic Parkinson's Disease

Summary: the major aim of this study is to determine the efficacy of a home-based treadmill walking program in improving walking capacity and quality of life in people with early mid-stage parkinson's disease(pd).

after alzheimer's disease, parkinson's disease (pd) is the most common degenerative neurological condition suffered by australians, with more than 30,000 australians having pd at any one time (parkinson's australia). hypokinesia, ie, reduced speed and amplitude of movement, is a major impairment of motor control affecting walking in people with pd. over time, the development of slow, shuffling walking contributes to loss of independence and falls, with devastating consequences for individuals with pd and their families(ashburn et al, 2001, playfer 2001). any decrease or delay in disability will reduce the personal and financial costs to individuals with pd, their families, health care resources and the community. a number of previous studies suggest exercise capacity and exercise habits are positively correlated. in people with mild parkinson's disease (canning et al 2005), walking capacity, measured as distance walked in the 6-min walk test, correlated with the amount of walking (r=.64, p\<0.01) performed each week. similarly, in an earlier study of people with mild to moderate parkinson's disease, regular exercise was associated with better exercise capacity (canning et al 1997). it appears, therefore, that proactive intervention aimed at developing good exercise habits in sedentary individuals with early to mid-stage parkinson's disease has the potential to reduce or delay walking difficulties. this study aims to establish the efficacy of a home-based treadmill walking program in providing an early intervention which addresses the primary motor control impairment of hypokinesia, while at the same time maintaining or improving exercise capacity.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic parkinson's disease * aged 30-80 years old * subjective disturbance of gait and / or unified parkinson's disease rating scale (updrs) gait subscore of 1 * sedentary, defined as performing less than 2 hours / week of leisure-time physical activity over the prior 3 months * have adapted to their current anti-parkinsonian medication for at least 2 weeks exclusion criteria: * motor fluctuations or dyskinesias which are disabling * require the use of a walking aid * more than one fall in the last 12 months * mini-mental state examination score of \<24 * exhibit other neurological or musculoskeletal conditions affecting walking * chest pain at rest or during exercise in the last 3 months, or heart attack, angioplasty or heart surgery in the last 6 months

Keywords: treadmill walking exercise automaticity quality of life
videographic feedback and walk rehabilitation in post-cerebrovascular accident

Conditions: Cerebrovascular Accident

Summary: cerebrovascular accident affects the majority of the elderly population and its frequency is constantly increasing. the resulting deficits are numerous and lead in particular to an alteration in the quality of walking and autonomy. numerous rehabilitation techniques have been described. in practice, correction instructions are often given by the therapist while the motor activity is being performed. walking is a complex activity, as is the processing of dual-task information in elderly stroke patients. it therefore appears interesting to separate the time of motor realization and that of correction instructions. investigators therefore propose firstly to film the patient during the performance of a walking activity and then, secondly, to analyse the video with the patient, which thus represents a source of delayed feedback. the main objective of the study is to observe the effects of this practice on walking speed. investigators are comparing two groups of patients: the control group receiving conventional rehabilitation and the experimental group receiving conventional rehabilitation plus sessions with the video tool. they expect to observe a greater improvement in walking speed in the experimental group.


Eligibility criteria:
inclusion criteria: * hospitalization for a first episode of cerebrovascular accident less than six months old, or nth stroke less than six months old, with no previous sequelae; * able to walk at least 10m without stopping, with or without technical assistance, but without human assistance, under supervision; exclusion criteria: * palliative or life-threatening situation; * a patient whose guardian or trustee is not readily available to provide information about the patient * neuro-cognitive disorder that prevents understanding of instructions, as determined by the clinician; * severe speech or language disorder that prevents the protocol from being carried out correctly; * hemineglect; * any previously known pathology altering the gait pattern, at the clinician's discretion (recent neurological, traumatological or orthopaedic pathologies, etc.); * visual disorder preventing viewing of the video; * hearing disorder preventing comprehension.
a dose-escalation study to assess the safety, tolerability, and pharmacokinetics of gdc-0032 in combination with docetaxel or with paclitaxel in patients with her2-negative locally recurrent or metastatic breast cancer or non-small cell lung cancer

Conditions: Breast Cancer, Non-small Lung Cancer

Summary: this is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of oral gdc-0032 administered in combination with either docetaxel or with paclitaxel. patients treated with the gdc-0032 and docetaxel have her2-negative locally recurrent or metastatic breast cancer or non-small cell lung cancer (nsclc). patients treated with the gdc-0032 and paclitaxel combination have human epidermal growth factor receptor 2 (her2)-negative locally recurrent or metastatic breast cancer. there are two potential stages within each arm of this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). once the maximum tolerated dose of gdc-0032 in a given arm has been established from dose escalation, additional patients with each combination will be enrolled in stage 2.


Eligibility criteria:
inclusion criteria: * age \>=18 years * for paclitaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease * for docetaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease or histologically documented advanced (stage iv) or recurrent nsclc * for participants with breast cancer: her2-negative disease as defined by local clinical guidelines * participants with nsclc to be treated with docetaxel need to have received at least one prior anti-cancer treatment regimen in an advanced setting and to have docetaxel be considered appropriate treatment * evaluable or measurable disease per response evaluation criteria in solid tumors (recist) v.1.1 * life expectancy \>=12 weeks * eastern cooperative oncology group (ecog) performance status of 0 or 1 at screening * adequate hematologic and end organ function * use of highly effective form of contraception exclusion criteria: * prior anti-cancer therapy * prior treatment with phosphoinositide 3-kinase (pi3k) inhibitor * known significant hypersensitivity to any components of study treatment * grade \>=2 peripheral neuropathy * type 1 or type 2 diabetes * grade \>=2 hypercholesterolemia or hypertriglyceridemia * congenital long qt syndrome * active congestive heart failure or ventricular arrhythmia
safety, pk and antiviral activity of pgt121 monoclonal antibody in hiv-uninfected and hiv-infected adults

Conditions: HIV Infection

Summary: this is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the pgt121 monoclonal antibody for hiv prevention and therapy.

this is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and anti-viral efficacy of the pgt121 monoclonal antibody for hiv prevention and therapy. pgt121 mab is a recombinant human igg1 monoclonal antibody that targets a v3 glycan-dependent epitope region of the hiv envelope protein. pgt121 mab was chosen for this study because it is potent, neutralizes a wide array of hiv viruses, and can prevent and treat simian-human immunodeficiency virus (shiv) in rhesus monkeys.

Eligibility criteria:
group 1 inclusion criteria: * hiv-uninfected males or females age 18-50 years old * willing to maintain low risk behavior for hiv infection group 1 exclusion criteria: * confirmed hiv-infection, pregnancy or lactation, significant acute or chronic disease and clinically significant laboratory abnormalities group 2 inclusion criteria: * hiv-infected males or females age 18-65 years old * on a stable antiretroviral regimen with hiv-1 rna plasma level \<50 copies/ml, cd4 cell count greater than or equal to 300 cells/ul group 2 exclusion criteria: * history of aids-defining illness within the previous 5 years, significant acute or chronic medical condition other than hiv infection, and clinically significant laboratory abnormalities group 3 inclusion criteria: * hiv-infected males or females age 18-65 * not on antiretroviral therapy for \> 6 months with detectable hiv-1 viral load between 100 and 100,000 copies/ml, cd4 cell count greater than or equal to 300 cells/ul group 3 exclusion criteria: * history of aids-defining illness within the previous 5 years, significant acute or chronic medical condition other than hiv infection, and clinically significant laboratory abnormalities
to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of day301 in participants with locally advanced or metastatic solid tumors

Conditions: Advanced or Metastatic Solid Tumors

Summary: this is a phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and anti-tumor activity of day301, a ptk7-directed antibody-drug conjugate in patients with advanced or metastatic solid tumors. the study comprises of 2 phases: phase 1a dose escalation where patients will be administered day301 at escalating dose levels to assess safety and tolerability, and to determine the maximum tolerated dose (mtd) and/or the recommended dose (rd); in phase 1b dose expansion, day301 will be evaluated in dose expansion cohorts.


Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors of the following histologies: * ovarian cancer * esophageal squamous cell carcinoma * triple-negative breast cancer * non-small cell lung cancer * small cell lung cancer * head and neck squamous cell carcinoma * gastric/gastroesophageal junction adenocarcinoma * cervical squamous cell carcinoma * endometrial cancers (patients must have been previously treated with standard of care systemic therapy, or for whom no standard therapy is available). * availability of tumor tissue sample (either an archival specimen or a fresh biopsy) at screening * measurable disease per response evaluation criteria in solid tumors (recist v1.1). * ecog performance status of 0 or 1. * adequate organ function. exclusion criteria: * prior use of ptk7 targeting treatment. * active or progressing brain metastases or evidence of leptomeningeal disease. * persistent toxicities from previous systemic antineoplastic treatments of grade \>1, excluding alopecia and vitiligo. * systemic antineoplastic therapy within 5 half-lives or 4 weeks, whichever is shorter, prior to first dose of the study drug, including investigational agents. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: advanced or metastatic solid tumors dose escalation dose expansion day301 ptk7-targeted antibody-drug conjugate